The 340B orphan drug exclusion may give drug makers a strong incentive to get an orphan designation for their drugs prescribed primarily for common diseases or conditions, a federal watchdog agency reminded Congress this month.

Drug Makers May Be Getting Orphan Drug Designations to Exploit 340B Orphan Drug Exclusion, HHS OIG Tells Congress

In Federal, Research/ReportsDecember 9, 2021447 Views

Tom Mirga

The ban on 340B pricing on orphan drugs for over 1,000 hospitals may give companies that make drugs used primarily for common diseases or conditions a strong financial incentive to get an orphan designation for those drugs, a federal watchdog agency recently reminded Congress.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Exact matches only

Search in title

Search in content

Search in excerpt

Hidden

*Sign up for news summaries and alerts from 340B Report